CN115737523A - Female bacteriostatic repair care solution based on cell complex factors - Google Patents
Female bacteriostatic repair care solution based on cell complex factors Download PDFInfo
- Publication number
- CN115737523A CN115737523A CN202211500034.8A CN202211500034A CN115737523A CN 115737523 A CN115737523 A CN 115737523A CN 202211500034 A CN202211500034 A CN 202211500034A CN 115737523 A CN115737523 A CN 115737523A
- Authority
- CN
- China
- Prior art keywords
- female
- extract
- bacteriostatic
- cell complex
- solution based
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000008439 repair process Effects 0.000 title claims abstract description 46
- 230000003385 bacteriostatic effect Effects 0.000 title claims abstract description 41
- 239000000284 extract Substances 0.000 claims abstract description 66
- 210000004027 cell Anatomy 0.000 claims abstract description 52
- 210000000130 stem cell Anatomy 0.000 claims abstract description 11
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 claims abstract description 8
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 claims abstract description 8
- 229960002152 chlorhexidine acetate Drugs 0.000 claims abstract description 8
- 239000000645 desinfectant Substances 0.000 claims abstract description 8
- 241000411851 herbal medicine Species 0.000 claims abstract description 8
- 210000002865 immune cell Anatomy 0.000 claims abstract description 8
- 229930014456 matrine Natural products 0.000 claims abstract description 8
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000004332 silver Substances 0.000 claims abstract description 7
- 229910052709 silver Inorganic materials 0.000 claims abstract description 7
- -1 silver ions Chemical class 0.000 claims abstract description 7
- 241000195649 Chlorella <Chlorellales> Species 0.000 claims description 23
- 210000003954 umbilical cord Anatomy 0.000 claims description 13
- 241000206618 Porphyridium Species 0.000 claims description 12
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 210000004700 fetal blood Anatomy 0.000 claims description 9
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 9
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 9
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 8
- 229920002498 Beta-glucan Polymers 0.000 claims description 8
- 210000005087 mononuclear cell Anatomy 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000013535 sea water Substances 0.000 claims description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- 241000972672 Phellodendron Species 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 241001083841 Aquatica Species 0.000 claims 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 5
- 239000003899 bactericide agent Substances 0.000 abstract description 5
- 239000000243 solution Substances 0.000 description 48
- 210000003491 skin Anatomy 0.000 description 21
- 238000005138 cryopreservation Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000005119 centrifugation Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000004140 cleaning Methods 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 241000195493 Cryptophyta Species 0.000 description 5
- 208000003251 Pruritus Diseases 0.000 description 5
- 244000052616 bacterial pathogen Species 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000009931 harmful effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000008591 skin barrier function Effects 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 229940069826 chlorella vulgaris extract Drugs 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000000474 nursing effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- 208000036649 Dysbacteriosis Diseases 0.000 description 2
- 208000027244 Dysbiosis Diseases 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000014429 Insulin-like growth factor Human genes 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 201000008100 Vaginitis Diseases 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000007140 dysbiosis Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PGLIUCLTXOYQMV-UHFFFAOYSA-N Cetirizine hydrochloride Chemical compound Cl.Cl.C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PGLIUCLTXOYQMV-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 description 1
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 241000972673 Phellodendron amurense Species 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- 206010040867 Skin hypertrophy Diseases 0.000 description 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 208000032159 Vaginal inflammation Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229940127130 immunocytokine Drugs 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007108 local immune response Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 238000004347 surface barrier Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a female bacteriostatic repair care solution based on cell complex factors, which comprises the following components: the female bacteriostatic repair care solution based on the cell complex factors does not contain Chinese herbal medicine extract and disinfectant. According to the female bacteriostatic repair care solution based on the cell extract, traditional bactericides such as silver ions, chlorhexidine acetate, matrine and the like are not added, and stem cell complex factors and immune cell complex factors are selected.
Description
Technical Field
The invention relates to the technical field of nursing products, in particular to a female bacteriostatic repair nursing liquid based on cell complex factors.
Background
World Health Organization (WHO) research on the health status of women worldwide indicates that: the incidence rate of gynecological diseases in the world is over 65 percent, and in women in the childbearing age, the incidence rate of gynecological diseases is over 70 percent; the worldwide number of infections of the genitourinary system reaches 3.33 hundred million people each year. In the last decade, the total incidence of common diseases of Chinese women slightly rises. The total disease rate of the common diseases of the women in the country in 2010 is 28.8 percent. Vaginitis is the first most common disease among women.
With the rising of female population, the increasing of working and living pressure, the improvement of living standard and health consciousness and the like in China, the gynecological diseases are more and more valued by people. Most of the time is in offices, on the way to work and on business, more time is in public places, and the silk stockings are often worn, so the ventilation property is poor, and the probability of being infected by the outside is continuously increased. In addition, the working pressure is large, the resistance of the patient is reduced, and therefore care of private parts at any time needs to be paid attention to, and germ infection is avoided. For this, a feminine care solution is generally used for cleaning care.
The existing personal care products are mainly divided into two categories: one kind is compounded by matrine, phellodendron bark and other Chinese herbal medicine extract, and has the main function of treating gynecological diseases and medicinal effect; the other is a disinfectant mainly with a sterilization function, which mainly comprises silver ions, chlorhexidine acetate and other components with sterilization functions. Both products can not be used for a long time in terms of components, and although the products have cleaning and sterilizing effects, the components not only have irritation to relatively fragile skin, but also can kill excessive normal flora, destroy acidic environment, reduce the immunity of the organism and destroy the self-cleaning effect of the organism.
Disclosure of Invention
Based on the situation, the female bacteriostatic repair care solution based on the cell complex factor is needed to solve the problems.
A female bacteriostatic repair care solution based on cell complex factors comprises: the female bacteriostatic repair care solution based on the cell complex factors does not contain Chinese herbal medicine extract and disinfectant.
In one embodiment, the stem cell complex factor is extracted after disruption of umbilical cord mesenchymal stem cells.
In one embodiment, the immune cell complex factor is extracted after the cord blood mononuclear cells are broken.
In one embodiment, the chlorella pumila extract is further included, and the concentration of the chlorella pumila extract is 5 to 15 mug/mL.
In one embodiment, the chlorella aquaticus extract is a lecithin-encapsulated chlorella aquaticus extract.
In one embodiment, the chlorella vulgaris extract is further included, and the concentration of the chlorella vulgaris extract is 5-15 mug/mL.
In one embodiment, the composition further comprises the porphyridium extract, and the concentration of the porphyridium extract is 2 to 10 mu g/mL.
In one embodiment, the fructo-oligosaccharide and beta-glucan are further included, the concentration of the fructo-oligosaccharide is 100-300 mu g/mL, and the concentration of the beta-glucan is 3-20 mu g/mL.
In one embodiment, the water-soluble paint further comprises p-hydroxyphenylallylaminobenzoic acid, hyaluronic acid and seawater, wherein the concentration of the p-hydroxyphenylallylaminobenzoic acid is 20 to 100 mu g/mL, and the volume ratio of the seawater to the water is 1 to 5:99 to 95 percent.
In one embodiment, the herbal extract comprises matrine extract and phellodendron extract, and the disinfectant comprises silver ions and chlorhexidine acetate.
According to the female bacteriostatic repair care solution based on the cell extract, traditional bactericides such as silver ions, chlorhexidine acetate, matrine and the like are not added, and stem cell complex factors and immune cell complex factors are selected.
Furthermore, the female bacteriostatic repair care solution based on the cell extract also comprises a chlorella pumila extract, a chlorella vulgaris extract and a porphyridium algae extract, wherein the algae extract can regulate prebiotics of vaginal flora, relieve allergy and resist inflammation, and the combination of the algae extract, a stem cell compound factor and an immune cell compound factor can be used for a long time without generating long-term accumulated harmful effects and can achieve the effects of bacteriostasis, self-cleaning and repair.
It should be noted that, in female private parts, a large number of microbes including bacteria, fungi, viruses and the like exist, which have important effects on maintaining skin ecological balance, self-purification and participating in skin mucous membrane physiological functions, when local immunity is reduced or the female is infected by external microbes, the microbial flora is unbalanced, which may become pathogenic bacteria to cause diseases, accumulated and non-metabolizable properties caused by using conventional bactericides and antibiotics, harm beneficial bacteria to cause further dysbacteriosis and possibly cause repeated inflammation. The recovery and maintenance of normal microbial colonies, the improvement of the immunity of private parts and the timely repair of tiny injury of mucous membranes at private parts have important significance for keeping the private parts healthy and preventing the infection of external germs.
According to the results of the test examples, the female bacteriostatic repair care solution based on the cell extract has a good cleaning and bacteriostatic effect, is mild and non-irritant to skin of female private parts, can play a role in nutrition and repair, and can be conveniently used at any time in daily life.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The invention discloses a female bacteriostatic repair care solution based on cell complex factors, which comprises the following components: the female bacteriostatic repair nursing liquid based on the cell complex factors does not contain Chinese herbal medicine extracting solution and disinfectant.
In the present invention, the concentration of the stem cell complex factor refers to the total protein concentration of the stem cell complex factor, and the concentration of the immunocytocomplex factor refers to the protein concentration of the immunocytocomplex factor.
According to the female bacteriostatic repair care solution based on the cell extract, traditional bactericides such as silver ions, chlorhexidine acetate, matrine and the like are not added, and stem cell complex factors and immune cell complex factors are selected.
Specifically, the Chinese herbal medicine extractive solution comprises matrine extractive solution and cortex Phellodendri extractive solution, and the disinfectant comprises silver ion and chlorhexidine acetate.
Namely, the female bacteriostatic repair care solution based on the cell extract does not contain matrine extract, phellodendron extract, silver ions and chlorhexidine acetate.
In addition, the female bacteriostatic repair care solution based on the cell extract does not contain other types of Chinese herbal medicine extract and disinfector.
Preferably, in the invention, the stem cell complex factor is obtained by extracting the umbilical cord mesenchymal stem cells after being crushed.
The cell complex factor extracted after the umbilical cord mesenchymal stem cells are crushed comprises Epidermal Growth Factor (EGF), stem Cell Factor (SCF), basic fibroblast growth factor (bFGF), keratinocyte Growth Factor (KGF), vascular Endothelial Growth Factor (VEGF), insulin-like growth factor (IGF), transforming growth factor-beta 1 (TGF-beta 1) and the like, can promote the self-repair of damaged tissues and cells, can regulate local immune response and inhibit inflammatory reaction.
Preferably, in the present invention, the immunocytokine complex is extracted from umbilical cord blood after breaking mononuclear cells.
The immune cell compound factor extracted after the cord blood mononuclear cells are crushed can enhance the local immunity and resist the invasion of external pathogenic bacteria.
Preferably, the female bacteriostatic repair care solution based on the cell extract further comprises a chlorella pumila extract, wherein the concentration of the chlorella pumila extract is 5-15 mu g/mL.
Specifically, the extract of Chlorella pumila is lecithin-coated.
The extract of the chlorella is wrapped by fat-soluble lecithin, and the wrapped microcapsule can penetrate into skin for allergy relief and inflammation resistance. By reducing proinflammatory interleukins causing abnormal leukocyte responses, the skin is calmed and relieved, and redness and itching are reduced. The skin allergy-prone skin is helped by enhancing the defense system of the skin, increasing the secretion of ceramide, enhancing the skin barrier, enhancing the immune system to resist external invasion. Through regulating and reducing proinflammatory interleukins IL-1 beta and IL-8, the skin is calmed and relieved. The skin barrier is enhanced, the immune system is enhanced to resist external invasion and the skin which is easy to be allergic is helped by regulating IFN-gamma (IFN-gamma) to enhance the defense system, increase the secretion of ceramide and finally enhance the skin barrier) and IL4 (antagonist of interferon). Through regulation and reduction of IL2 (IL 2 has an anti-itch effect, which is closely related to allergic inflammation, severe cutaneous pruritus and dry skin), pruritus, erythra and redness are reduced.
Preferably, the female bacteriostatic repair care solution based on the cell extract further comprises a chlorella extract, and the concentration of the chlorella extract is 5 to 15 mu g/mL.
The chlorella contains an efficient repairing factor, has high activity and can provide more nutrition for skin. The plant-derived repair factor can restore cell skin vitality, help to renew keratinocytes, promote deep cell growth, and restore damaged skin surface barriers. Up-regulates the internal growth factor TGF-alpha and the skin thickening signaling factor DKK-1.
Preferably, the female bacteriostatic repair care solution based on the cell extract further comprises a porphyridium extract, and the concentration of the porphyridium extract is 2-10 mu g/mL.
The porphyridium extract extracted from the natural porphyridium can obviously increase the water content of the skin and keep moisture for 24 hours. And can improve skin texture, reduce roughness and smooth private skin.
The female bacteriostatic repair care solution based on the cell extract also comprises a floating chlorella extract, a chlorella extract and a porphyridium extract, wherein the algae extract can regulate prebiotics of vaginal flora, relieve allergy and resist inflammation, and the combination of the algae extract, a stem cell compound factor and an immune cell compound factor can be used for a long time without generating long-term accumulated harmful effect and can achieve the effects of bacteriostasis, self-cleaning and repair.
Preferably, the female bacteriostatic repair care solution based on the cell extract further comprises fructo-oligosaccharide and beta-glucan, wherein the concentration of the fructo-oligosaccharide is 100-300 mu g/mL, and the concentration of the beta-glucan is 3-20 mu g/mL.
The fructo-oligosaccharide can regulate flora on the surface of skin, promote activity of beneficial bacteria on the body surface, inhibit harmful bacteria, and restore the microbial ecological environment on the body surface. Providing skin and epithelial cell nutrition, maintaining cell vitality, promoting repair, recovering skin barrier function, increasing immunity function, and ensuring skin to adapt to environment and life style.
Preferably, the female bacteriostatic repair care solution based on the cell extract further comprises p-hydroxyphenylallylaminobenzoic acid, hyaluronic acid and seawater, wherein the concentration of the p-hydroxyphenylallylaminobenzoic acid is 20-100 mug/mL, and the volume ratio of the seawater to the water is 1-5: 99 to 95.
The p-hydroxyphenylallylaminobenzoic acid which is an active ingredient extracted from the oat can obviously relieve the abnormal condition of the skin, relieve the inflammatory reaction caused by histamine release and quickly relieve the pruritus, the red swelling and the blister caused by various conditions.
It should be noted that, in female private parts, a large number of microbes including bacteria, fungi, viruses and the like exist, which have important effects on maintaining skin ecological balance, self-purification and participating in skin mucous membrane physiological functions, when local immunity is reduced or the female is infected by external microbes, the microbial flora is unbalanced, which may become pathogenic bacteria to cause diseases, accumulated and non-metabolizable properties caused by using conventional bactericides and antibiotics, harm beneficial bacteria to cause further dysbacteriosis and possibly cause repeated inflammation. The recovery and maintenance of normal microbial colonies, the improvement of immunity of private parts and the timely repair of tiny injury of mucous membranes at private parts have important significance for keeping the private parts healthy and preventing the infection of external germs.
According to the results of the test examples, the female bacteriostatic repair care solution based on the cell extract has a good cleaning and bacteriostatic effect, is mild and non-irritant to skin of female private parts, can play a role in nutrition and repair, and can be conveniently used at any time in daily life.
The following are specific examples.
In particular embodiments, the drug sources involved are as follows:
chlorella extract is obtained from GREEANLTECHS.L of Spain
BioSKN；
The Porphyridium extract is HYDRINTENSE from Givaudan France SAS, switzerland;
the extract of Chlorella pumila is obtained from fructooligosaccharide obtained from GREENALTECHS.L of Spain and is obtained from Biotech limited of Shandong mountain
beta-Glucan from Tri-friend Zhi Biotech, inc. of Beijing
P-hydroxyphenylallylaminobenzoic acid available from Donza (Shanghai) Co., ltd
Example 1: extraction of umbilical cord mesenchymal stem cell complex factor
Cell resuscitation
1) 1 human umbilical cord mesenchymal stem cell (2X 10) extracted from umbilical cord of healthy donor is taken out from synchysis biological umbilical cord mesenchymal stem cell public bank 7 ) And (4) carrying out water bath in a water bath kettle at 37 ℃, slightly shaking, and taking out the ice blocks when the ice blocks in the freezing storage pipe are about to be completely melted. The frozen tube is quickly transferred to a biological safety cabinet after being subjected to surface disinfection. The resuscitated cell suspension was aspirated and transferred into 40mL of physiological saline pre-cooled at 4 ℃.500g centrifugal force, 10 minutes, speed up 9, speed down 7, centrifugation.
2) After centrifugation, the tube was washed again with 40mL of physiological saline, and 20mL of the tube was transferred to another centrifuge tube. 500g,10 min, increasing speed by 9, decreasing speed by 7, and centrifuging.
3) Centrifuging for later use.
Ultrasonic disruption
1) The prepared cells were resuspended in 15mL of physiological saline, transferred to a 50mL centrifuge tube, and the centrifuge tube was placed in ice.
2) HN-250M hand-held ultrasonic cell crusher sets up: the specification of the amplitude transformer: phi 3; power: 25%, sonication time: 3s, ultrasound gap time: 2s, total ultrasound time: and 2h.
3) After the completion of the disruption, 500. Mu.L of the suspension was centrifuged at 5000rpm for 10min.
4) After centrifugation was complete, the supernatant was retained.
5) The total protein concentration in the supernatant was measured to be 13.3. Mu.g/mL using a Nanodrop2000 spectrophotometer.
Protein concentration
The supernatant was transferred to a 50mL ultrafiltration centrifuge tube (Millipore) and centrifuged at 4000g for 45min at 9 and 7 ramp-down rates. And after the centrifugation is finished, obtaining the umbilical cord mesenchymal stem cell compound factor solution.
The total protein concentration of the umbilical cord mesenchymal stem cell complex factor solution measured by a Nanodrop2000 spectrophotometer was 167.8. Mu.g/mL.
Example 2: extraction of umbilical cord blood mononuclear cell complex factor
1) Centrifuging 80mL of newborn umbilical cord blood of a healthy donor for 8min under the centrifugal force of 500g, sucking an upper yellowish plasma layer by a pipette after centrifugation is finished, transferring the supernatant yellowish plasma layer into a new 50mL centrifugal tube, and inactivating the obtained plasma at 56 ℃ for 30min to obtain inactivated umbilical cord plasma for later use;
2) The residual liquid is concentrated blood cells, the concentrated blood cells are diluted by physiological saline, the concentrated blood cells are subjected to density gradient centrifugal separation of human lymphocyte separation liquid, centrifugation is carried out for 20min under 840g of centrifugal force, a tunica albuginea layer (UCBMC, umbilical cord blood mononuclear cells) at the lower layer is sucked, after the solution is re-suspended by the physiological saline, centrifugation and washing are carried out twice at 300g of centrifugal force for 8min, and the UCBMC is obtained;
3) Inoculating the UCBMC cells obtained into lymphocyte serum-free medium, and processing the UCBMC cells with the inactivated umbilical cord plasma obtained in 1) at a volume concentration of 10% and IL-2 content of 300U/mL at 37 deg.C and 5% 2 Carrying out amplification culture for 72 hours under the condition, finally carrying out centrifugal separation, and respectively collecting cells and supernate;
4) Resuspending the cells obtained in the step 3) into 1mL of physiological saline, transferring the cells into a 1mL cryopreservation tube, putting the cryopreservation tube on a cryopreservation tube frame, putting the cryopreservation tube frame into a foam box, and adding ice into the foam box, wherein the height of the ice cannot exceed the height of the cryopreservation tube; sterilizing the foam box, putting the foam box into a biological safety cabinet, and taking off a freezing storage tube cover;
5) Using an HN-250M handheld ultrasonic cell crusher in a biological safety cabinet, inserting an amplitude transformer 10mm below the liquid level of the cell suspension of the cryopreservation tube, and paying attention to the fact that the amplitude transformer cannot contact the bottom or the wall of the cryopreservation tube;
6) Setting an ultrasonic crusher: power: 30%, sonication time: 3s, ultrasound gap time: 2s, total ultrasound time: and 4h.
7) After the cell disruption was completed, the cell debris and the factor solution were aspirated by a pipette gun, transferred to a 1.5mL centrifuge tube at 10000rpm for 10min, and centrifuged.
8) After centrifugation, the supernatant was aspirated, transferred to a 2mL cryopreservation tube, and then added with physiological saline to 1mL to obtain cytokine solution 1. The total protein concentration in the cytokine solution 1 was measured to be 26.4. Mu.g/mL using a Nanodrop2000 spectrophotometer.
9) Transferring the supernatant obtained in step 3) to an ultrafiltration centrifugal tube, 4000g,30min, increasing the speed by 9 steps, reducing the speed by 7 steps, and centrifuging.
10 After the centrifugation is finished, sucking out the concentrated factor solution by using a 100 mu L gun head, transferring the concentrated factor solution to a 2mL cryopreservation tube, adding 500 mu L of normal saline into an ultrafiltration centrifugal tube, washing a filter membrane component, sucking out the concentrated factor solution by using the 100 mu L gun head, transferring the concentrated factor solution to the same cryopreservation tube, adding the normal saline to adjust the volume to 1mL to obtain the cytokine solution 2, and measuring the total protein concentration of the cytokine solution 2 to be 11.7 mu g/mL by using a Nanodrop2000 spectrophotometer.
11 0.08mL of the cytokine solution 1 and 0.02mL of the cytokine solution 2 were mixed to obtain a cord blood mononuclear cell composite factor solution.
Example 3
Adding 80mL of water into a main kettle, stirring and heating to 82.5 +/-2.5 ℃, and preserving heat and stirring.
Cooling to 42.5 ℃ +/-2.5 ℃ while stirring, adding 1mL of fructo-oligosaccharide solution, 1mL of beta-glucan solution, 1mL of porphyridium extract solution, 1mL of chlorella extract solution in water, 0.21mL of p-hydroxyphenylallylaminobenzoic acid, 1mL of hyaluronic acid, 5mL of seawater, 3mL of umbilical cord mesenchymal stem cell complex factor solution and 0.1mL of umbilical cord blood mononuclear cell complex factor solution, and stirring.
Cooling water was turned on with stirring and cooled to 32.5 ℃. + -. 2.5 ℃.
And (4) sampling and detecting, and filling to obtain the female bacteriostatic repairing care solution based on the cell extract.
Test example
10 female subjects with vaginal inflammation aged 30-60 years were recruited to use the cell extract-based female bacteriostatic repair solution of example 3 for one month, sprayed twice a day in the morning and evening, and the results are shown in table 1 below.
TABLE 1
As can be seen from table 1, the female bacteriostatic repair care solution based on the cell extract in example 3 can be used for a long time without generating long-term accumulated harmful effects, and can achieve bacteriostatic, self-cleaning and repair effects.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the claims. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Claims (10)
1. A female bacteriostatic repair care solution based on cell complex factors is characterized by comprising: the female bacteriostatic repair care solution based on the cell complex factors does not contain Chinese herbal medicine extract and disinfectant.
2. The female bacteriostatic repair care solution based on the cell complex factor as claimed in claim 1, wherein the stem cell complex factor is extracted after umbilical cord mesenchymal stem cells are crushed.
3. The female bacteriostatic repair care solution based on the cell complex factor as claimed in claim 2, wherein the immune cell complex factor is extracted after the mononuclear cells of the umbilical cord blood are crushed.
4. The female bacteriostatic repair care solution based on the cell complex factor as claimed in claim 3, which is characterized by further comprising a chlorella aquaticus extract, wherein the concentration of the chlorella aquaticus extract is 5 to 15 μ g/mL.
5. The female bacteriostatic repair care solution based on the cell complex factor as claimed in claim 4, wherein the extract of the chlorella aquatica is lecithin-coated extract of the chlorella aquatica.
6. The female bacteriostatic repair care solution based on the cell complex factor as claimed in claim 4, which is characterized by further comprising a chlorella extract, wherein the concentration of the chlorella extract is 5 to 15 μ g/mL.
7. The female bacteriostatic repair care solution based on the cell complex factor as claimed in claim 6, which is characterized by further comprising porphyridium extract, wherein the concentration of the porphyridium extract is 2 to 10 μ g/mL.
8. The female bacteriostatic repair care solution based on the cell complex factor as claimed in claim 7, which further comprises fructo-oligosaccharide and beta-glucan, wherein the concentration of the fructo-oligosaccharide is 100-300 μ g/mL, and the concentration of the beta-glucan is 3-20 μ g/mL.
9. The female bacteriostatic repair care solution based on the cell complex factor as claimed in claim 8, which further comprises p-hydroxyphenylallylaminobenzoic acid, hyaluronic acid and seawater, wherein the concentration of the p-hydroxyphenylallylaminobenzoic acid is 20 to 100 μ g/mL, and the volume ratio of the seawater to the water is 1 to 5:99 to 95.
10. The female bacteriostatic repair care solution based on the cell complex factor according to any one of claims 1 to 9, wherein the Chinese herbal medicine extract comprises matrine extract and phellodendron extract, and the disinfectant comprises silver ions and chlorhexidine acetate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211500034.8A CN115737523A (en) | 2022-11-28 | 2022-11-28 | Female bacteriostatic repair care solution based on cell complex factors |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211500034.8A CN115737523A (en) | 2022-11-28 | 2022-11-28 | Female bacteriostatic repair care solution based on cell complex factors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115737523A true CN115737523A (en) | 2023-03-07 |
Family
ID=85339215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211500034.8A Pending CN115737523A (en) | 2022-11-28 | 2022-11-28 | Female bacteriostatic repair care solution based on cell complex factors |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115737523A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107625680A (en) * | 2017-09-26 | 2018-01-26 | 杭州梵琳科技有限公司 | Shu Min aquas and preparation method thereof |
| CN108823156A (en) * | 2018-07-04 | 2018-11-16 | 陕西神州生物技术有限公司 | For the clinical grade human umbilical cord mesenchymal stem cells composite factor of reparation and the preparation method of freeze-dried powder |
| CN108992662A (en) * | 2018-08-23 | 2018-12-14 | 杭州元研细胞生物科技有限公司 | A kind of vagina of the factor containing mescenchymal stem cell is spraying and preparation method thereof |
| CN111214431A (en) * | 2020-02-28 | 2020-06-02 | 深圳市芙丽嘉生物科技有限公司 | Composition for promoting skin recovery and application thereof |
| CN114652748A (en) * | 2022-03-29 | 2022-06-24 | 湖南有美生物科技有限公司 | Preparation method and application of medical gynecological lotion containing stem cell bacteriostatic factors |
-
2022
- 2022-11-28 CN CN202211500034.8A patent/CN115737523A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107625680A (en) * | 2017-09-26 | 2018-01-26 | 杭州梵琳科技有限公司 | Shu Min aquas and preparation method thereof |
| CN108823156A (en) * | 2018-07-04 | 2018-11-16 | 陕西神州生物技术有限公司 | For the clinical grade human umbilical cord mesenchymal stem cells composite factor of reparation and the preparation method of freeze-dried powder |
| CN108992662A (en) * | 2018-08-23 | 2018-12-14 | 杭州元研细胞生物科技有限公司 | A kind of vagina of the factor containing mescenchymal stem cell is spraying and preparation method thereof |
| CN111214431A (en) * | 2020-02-28 | 2020-06-02 | 深圳市芙丽嘉生物科技有限公司 | Composition for promoting skin recovery and application thereof |
| CN114652748A (en) * | 2022-03-29 | 2022-06-24 | 湖南有美生物科技有限公司 | Preparation method and application of medical gynecological lotion containing stem cell bacteriostatic factors |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108524601B (en) | Vaginal gel containing pleiotropic factors and preparation method thereof | |
| EA026198B1 (en) | Multipurpose gel for vaginal dryness with direct and delayed effect | |
| US10478463B2 (en) | External-use medicament for cleaning and care of the ovaries, vagina, and vulva | |
| CN110604810A (en) | Hydrolyzed collagen gel for gynecology and preparation method thereof | |
| CN112089883B (en) | Medical cold compress dressing and preparation method thereof | |
| CN113057930A (en) | Mite-removing face cream containing rosemary and preparation method thereof | |
| WO2015115778A1 (en) | Method for preparing medicinal herb composition having atopic immune system strengthening and anticancer effects | |
| CN111529470B (en) | Compound acne-removing and allergy-relieving gel and preparation method thereof | |
| CN107961399A (en) | A kind of water-based body lotion containing complex antimicrobials | |
| CN111759885A (en) | Sophora flavescens composition, sophora flavescens gel and preparation method thereof | |
| KR102148808B1 (en) | Feminine Cleanser Composition Comprising Natural Antimicrobial Agents | |
| CN111150787A (en) | Traditional Chinese veterinary medicine premix and preparation method thereof | |
| CN115737523A (en) | Female bacteriostatic repair care solution based on cell complex factors | |
| KR101168225B1 (en) | Fermented extract of mixed biodrugs and vagina cleaning composition for woman containing the extract | |
| CN104288552A (en) | Vagina-cleaning care solution and preparation method thereof | |
| CN106344613A (en) | Application of NK cell stock solution in preparation of medicine for treating skin diseases | |
| CN116210732A (en) | Preparation method and application of mite-removing and odor-removing plant extract combination liquid | |
| CN105193686A (en) | Female care solution and preparation method thereof | |
| CN104840483A (en) | Medicine composition for treating skin wounds and medicinal preparation thereof | |
| CN109432204B (en) | Silver ion spray and preparation method thereof | |
| CN102793832B (en) | Novel micro-ecological modulator and preparation method thereof | |
| WO2017193509A1 (en) | Bionic gynecological lotion and preparation method therefor | |
| CN106581172B (en) | Medicine for preventing and treating mycotic vaginitis, trichomonas vaginitis and senile vaginitis and preparation method thereof | |
| CN112089827A (en) | Prebiotic-containing pharmaceutical composition for regulating female vaginal microecological balance, preparation and use thereof | |
| CN110974935A (en) | Antibacterial nursing gel containing fullerene C60 component and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |